At the 61st ASH Annual Meeting & Exposition, Sabina Chiaretti, “Sapienza” University of Rome, discusses her presentation: Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. A Single Center Experience.
Questions
1. What are the limitations of current therapeutic options for patients with relapsed/refractory acute lymphoblastic leukemia (ALL)? (0:05)
2. What is the mechanism of action of blinatumomab? (0:54)
3. What were the major findings of your retrospective study? (1:46)
4. What did the study findings teach us about the safety profile of blinatumomab and how to manage toxicities? (2:58)
5. How are these findings likely to impact on clinical practice? (4:43)
Sabina Chiaretti has received consultancy fees from Amgen, Shire, Pfizer and incyte.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
